Evidence map›Paper›PMID 26650549›Full record

ArticleProtein science : a publication of the Protein Society2016

Analog sensitive chemical inhibition of the DEAD-box protein DDX3.

Stephen N Floor, Krister J Barkovich, Kendall J Condon, Kevan M Shokat, Jennifer A Doudna

Open access · bronzeAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Inhibition of the Dead Box RNA Helicase 3 Prevents HIV-1 Tat and Cocaine-Induced Neurotoxicity by Targeting Microglia Activation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Stephen N FloorDepartment of Molecular and Cell Biology, University of California, Berkeley, California.
Krister J BarkovichDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, California.
Kendall J CondonDepartment of Molecular and Cell Biology, University of California, Berkeley, California.
Kevan M ShokatDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, California.
Jennifer A DoudnaDepartment of Molecular and Cell Biology, University of California, Berkeley, California.
Howard Hughes Medical Institute · USUniversity of California, Berkeley · USUniversity of California, San Francisco · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6M
RESEARCH TRAINING IN CHEMISTRY AND CHEMICAL BIOLOGYT32GM064337 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2002 to 2021
$7.8M
Uncovering the role of individual RNA helicases in cancer through specific chemical inhibitionF30CA203522 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BARKOVICH, KRISTER · 2016 to 2018
$121k
NCI NIH HHS F30 CA203522NIGMS NIH HHS T32 GM007618NIGMS NIH HHS T32 GM064337
6 · The paper itself

Abstract

Proper maintenance of RNA structure and dynamics is essential to maintain cellular health. Multiple families of RNA chaperones exist in cells to modulate RNA structure, RNA-protein complexes, and RNA granules. The largest of these families is the DEAD-box proteins, named after their catalytic Asp-Glu-Ala-Asp motif. The human DEAD-box protein DDX3 is implicated in diverse biological processes including translation initiation and is mutated in numerous cancers. Like many DEAD-box proteins, DDX3 is essential to cellular health and exhibits dosage sensitivity, such that both decreases and increases in protein levels can be lethal. Therefore, chemical inhibition would be an ideal tool to probe the function of DDX3. However, most DEAD-box protein active sites are extremely similar, complicating the design of specific inhibitors. Here, we show that a chemical genetic approach best characterized in protein kinases, known as analog-sensitive chemical inhibition, is viable for DDX3 and possibly other DEAD-box proteins. We present an expanded active-site mutant that is tolerated in vitro and in vivo, and is sensitive to chemical inhibition by a novel bulky inhibitor. Our results highlight a course towards analog sensitive chemical inhibition of DDX3 and potentially the entire DEAD-box protein family.

Indexed as

Adenosine MonophosphateAmino Acid SequenceCatalytic DomainDEAD-box RNA HelicasesHumansModels, MolecularMutationRNAThiazoles2-anilino-5-thiazolinoneAdenosine MonophosphateDDX3X protein, humanDEAD-box RNA HelicasesRNAThiazoleschemical geneticsDDX3 inhibitorDEAD-box proteinsprotein engineeringRNAsmall-molecule inhibitor

Identifiers

PMID26650549
PMCPMC4815421
OpenAlexW2296655335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.